Albuvirtide vs CPT31

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV gp41 · full HIV pipeline

Albuvirtide · Aikening

Marketed by Frontier Biotechnologies

Phase 3 in HIVPeptide (fusion inhibitor)
Partial signal

NCT02369965 · Phase 3 · completed

The study randomly assigned 418 participants to an active comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: July 2028 · NCT07727642 (registry estimate)

Reported efficacy

Percentage of participants of virological suppression at Week 48 (Through Week 48): Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met. (met)

Result source: NCT02369965

CPT31

Developed by Navigen

Phase 1 in HIVD-peptide
Weak signal

NCT04672083 · Phase 1 · completed

The study randomly assigned healthy volunteers to CPT31 or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. It reported that no participant in any group, active or placebo, had a serious adverse event, but the study measured only safety and drug levels in healthy volunteers rather than any HIV outcome. Its registered primary outcome on ClinicalTrials.gov is "Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of subjects experiencing serious adverse events (SAEs): No participant in any cohort or the placebo group had a serious adverse event (the primary outcome counts serious events only; non-serious events are reported separately) (not_applicable)

Result source: NCT04672083

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlbuvirtideCPT31
HIV-1 RNA below 50 copies/mL (week 48)—Not posted · NCT02369965—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT02369965—Not reported
CD4 count, change (week 48)—Not posted · NCT02369965—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Albuvirtide
—Not posted · NCT02369965
CPT31
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Albuvirtide
—Not posted · NCT02369965
CPT31
—Not reported

CD4 count, change (week 48)

Albuvirtide
—Not posted · NCT02369965
CPT31
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Albuvirtide: 0 of 4 rows · CPT31: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlbuvirtideCPT31
Dropout rate—
0%0.24 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
show 3 more results
0%0.12 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
0%0.04 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
16.7%0.01 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
Discontinued due to AEs—
—0.24 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
show 3 more results
—0.12 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
—0.04 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
—0.01 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
Serious AEs—
0%0.24 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
show 3 more results
0%0.12 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
0%0.04 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
0%0.01 mg/kg
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
Most frequent reported AEs—
0.24 mg/kg
injection site erythema 83.3% (placebo 0%)
injection site induration 50% (placebo 0%)
injection site pain 50% (placebo 0%)
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
show 3 more results
0.12 mg/kg
injection site erythema 16.7% (placebo 0%)
injection site pain 16.7% (placebo 0%)
injection site pruritis 16.7% (placebo 0%)
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
0.04 mg/kg
dermatitis 0% (placebo 12.5%)
dry skin 0% (placebo 12.5%)
injection site erythema 0% (placebo 0%)
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1
0.01 mg/kg
dermatitis 0% (placebo 12.5%)
dry skin 0% (placebo 12.5%)
injection site erythema 0% (placebo 0%)
NCT04672083 · Phase 1 · monotherapy · HIV · phase 1

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Albuvirtide

Virologic Suppression 80.4% vs 66% NRTI+LPV/r control @ 48wk
responder rate · % of participants
NCT02369965 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuvirtide's landscape · CPT31's landscape